Lion Biotechnologies’ CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate’s Immunotherapy Forum on January 27
January 24 2014 - 8:00AM
Business Wire
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief
Executive Officer Manish Singh, Ph.D., will preside over the
introductory session of the Phacilitate Immunotherapy Forum on
Monday, January 27, 2014. Titled “Overviewing key trends in
immunotherapy R&D investment, collaboration and pipeline
strategies,” the session will include presentations by executives
from biotechnology and pharmaceutical companies, and a panel
discussion with life science industry and venture capital
executives.
In addition, Lion Biotechnologies’ Vice President, Product
Development and Manufacturing, James G. Bender, Ph.D., will be a
panelist in a key breakfast briefing titled “Development by design
– a model for managing comparability risks and optimizing process
development for Cell Therapy and Immunotherapy processes,” on
Wednesday, January 29.
The Immunotherapy Forum is being held January 27-29 at The Grand
Hyatt Hotel in Washington D.C., and is part of Phacilitate’s
Washington Bioleaders 2014 Conference.
“We are pleased to have an important role in this year’s
Immunotherapy Forum, which will have an audience of 500-600
executives from the pharma and biotech industries, as well as key
external stakeholders, including the world's regulators, public and
private sector investors, NGOs, payers and analysts,” said Dr.
Singh. “The conference provides an excellent opportunity to network
with leaders from industry, government and the investment
community, and discuss recent progress in our T-cell development
program.”
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of
T-cells and engineered T-cells for the treatment of various
cancers. The company's lead product candidate is a ready-to-infuse
autologous T-cell therapy utilizing tumor-infiltrating lymphocytes
(TILs) for the treatment of patients with Stage IV metastatic
melanoma, and is based on a clinical CRADA with the National Cancer
Institute along with physician-sponsored investigational therapy at
the MD Anderson Cancer Center and the H. Lee Moffitt Cancer &
Research Institute. For more information, please visit
http://www.lionbio.com.
INVESTOR CONTACT:LHADon MarkleySenior Vice
President310-691-7100dmarkley@lhai.com